Arrowhead Pharma Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
On Nov. 18, 2025, Arrowhead Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO…